2-chloro-3-nitro-6-trifluoromethyl-pyridin-4-ylamine | 947144-40-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2-chloro-3-nitro-6-trifluoromethyl-pyridin-4-ylamine
• 英文别名: 2-Chloro-3-nitro-6-trifluoromethyl-pyridin-4-ylamine；2-chloro-3-nitro-6-(trifluoromethyl)pyridin-4-amine
• CAS: 947144-40-3
• 化学式: C₆H₃ClF₃N₃O₂
• 分子量: 241.557
• InChiKey: WFDRPMOTCMWHSU-UHFFFAOYSA-N

物化性质

• 沸点：
  349.9±42.0 °C(Predicted)
• 密度：
  1.698±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-chloro-3-nitro-6-trifluoromethyl-pyridin-4-ylamine 在 Me-THF 、 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection

  摘要：

  The synthesis and structure-activity relationships of a series of novel interferon inducers are described. Pharmacokinetic studies and efficacy assessment of a series of 8-oxo-3-deazapurine analogues led to the identification of compound 33, a potent and selective agonist of the TLR7 receptor with an excellent in vivo efficacy profile in a mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.092
• 作为产物：
  描述：

  benzyl-(2-chloro-3-nitro-6-trifluoromethylpyridin-4-yl)amine 在 硫酸 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 0.5h， 生成 2-chloro-3-nitro-6-trifluoromethyl-pyridin-4-ylamine
  参考文献：
  名称：

  NOVEL PHARMACEUTICALS

  摘要：

  本发明涉及公式（I）的免疫应答调节剂，通过对Toll样受体（TLRs）的激动作用具有选择性，其用途，其制备方法，用于其制备的中间体以及含有所述抑制剂的组合物。这些抑制剂在包括治疗传染病（如肝炎（例如HCV，HBV），遗传相关病毒感染和癌症在内的各种治疗领域中具有用途。

  公开号：

  US20070197478A1

文献信息

• NOVEL PHARMACEUTICALS
  申请人：Jones Peter

  公开号：US20070197478A1

  公开（公告）日：2007-08-23

  The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.

  本发明涉及公式（I）的免疫应答调节剂，通过对Toll样受体（TLRs）的激动作用具有选择性，其用途，其制备方法，用于其制备的中间体以及含有所述抑制剂的组合物。这些抑制剂在包括治疗传染病（如肝炎（例如HCV，HBV），遗传相关病毒感染和癌症在内的各种治疗领域中具有用途。
• Pharmaceuticals
  申请人：Pfizer Inc.

  公开号：US07691877B2

  公开（公告）日：2010-04-06

  The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.

  本发明涉及公式（I）的免疫应答调节剂，其通过Toll样受体（TLRs）的激动作用选择性地发挥作用，其应用，制备过程，制备中使用的中间体以及含有所述抑制剂的组合物。这些抑制剂在多种治疗领域中具有实用性，包括治疗传染性疾病，如肝炎（例如HCV，HBV），遗传相关的病毒感染和癌症。
• Discovery of a highly potent series of TLR7 agonists
  作者：Peter Jones、David C. Pryde、Thien-Duc Tran、Fiona M. Adam、Gerwyn Bish、Frederick Calo、Guiseppe Ciaramella、Rachel Dixon、Jonathan Duckworth、David N.A. Fox、Duncan A. Hay、James Hitchin、Nigel Horscroft、Martin Howard、Carl Laxton、Tanya Parkinson、Gemma Parsons、Katie Proctor、Mya C. Smith、Nicholas Smith、Amy Thomas

  DOI：10.1016/j.bmcl.2011.07.076

  日期：2011.10

  The discovery of a series of highly potent and novel TLR7 agonist interferon inducers is described. Structure- activity relationships are presented, along with pharmacokinetic studies of a lead molecule from this series of N9-pyridylmethyl-8-oxo-3-deazapurine analogues. A rationale for the very high potency observed is offered. An investigation of the clearance mechanism of this class of compounds in rat was carried out, resulting in aldehyde oxidase mediated oxidation being identified as a key component of the high clearance observed. A possible solution to this problem is discussed. (C) 2011 Elsevier Ltd. All rights reserved.
• 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS
  申请人：Pfizer Limited

  公开号：EP1987030A1

  公开（公告）日：2008-11-05
• US7691877B2
  申请人：——

  公开号：US7691877B2

  公开（公告）日：2010-04-06